Amylyx Pharmaceuticals Financial Results
Amylyx Pharmaceuticals reported third quarter 2026 financial results and provided a business update, highlighting positive Phase 3 LUCIDITY trial results for avexitide in post-bariatric hypoglycemia. The company remains on track to submit a New Drug Application (NDA) by the end of 2026 and recently strengthened its balance sheet with approximately $545 million in net proceeds from a public offering.
“The third quarter was a transformational period for Amylyx, as we reported positive topline results from the Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia, bringing us one step closer to potentially delivering a first ever FDA-approved treatment to people living with PBH.”
Joshua Cohen and Justin Klee, Co-CEOs of Amylyx